Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Brigatinib Before Brain Irradiation Trial (B3i Trial): A Phase II Trial of Brigatinib Alone for Brain Metastases From ALK+ Lung Cancer

NCT04634110 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT04634110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04634110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Brigatinib Before Brain Irradiation Trial (B3i Trial): A Phase II Trial of Brigatinib Alone for Brain Metastases From ALK+ Lung Cancer
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Terminated
Start date
November 17, 2020
Completion date
April 14, 2022
Enrollment
1 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, lung cancer